Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SpringWorks gets EC orphan drug designation for NF1 treatment mirdametinib
Image: SpringWorks has secured EC orphan drug designation for mirdametinib to treat neurofibromatosis type 1. Photo: courtesy of Bruno Glätsch from Pixabay.
Image: SpringWorks has secured EC orphan drug designation for mirdametinib to treat neurofibromatosis type 1. Photo: courtesy of Bruno Glätsch from Pixabay.